Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
Yannis K. Valtis(Brigham and Women's Hospital), Lori Muffly(Stanford University), Melhem Solh(Johns Hopkins Hospital), Rawan Faramand(Moffitt Cancer Center), Wendy Stock(University of Chicago), Matthew L. Ulrickson, Divya Koura(University of California San Diego), Marlise R. Luskin(Dana-Farber Cancer Institute), Matthew P. Connor(Hospital of the University of Pennsylvania), Bijal Shah(Boston College), Omer Jamy(University of Alabama at Birmingham Hospital), Caspian Oliai(APLA Health), Jessica Leonard(Oregon Health & Science University), Georgia R. Lill(Los Angeles Medical Center), Tamer Othman(City Of Hope National Medical Center), Vivian Irizarry Gatell(Southwestern Medical Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Ibrahim Aldoss(City of Hope), Olalekan O. Oluwole(Vanderbilt University), Gregory W. Roloff(University of Chicago), Razan Mohty(University of Alabama at Birmingham), Noam E. Kopmar(University of Washington), Evan C. Chen(Dana-Farber Cancer Institute), Rasmus T. Hoeg(University of California, Davis), LaQuisa C. Hill(Baylor College of Medicine), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Ibrahim N. Muhsen, Muthu Sendhil Kumaran(Post Graduate Institute of Medical Education and Research), Caitlin Guzowski(Northside Hospital), Karamjeet Sandhu, Jae H. Park(University of Tennessee at Knoxville), Talal Hilal(WinnMed), Clayton Jackson(HRL Laboratories (United States)), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Kaitlyn C. Dykes(University of California San Diego), Hrishikesh K. Srinagesh(Stanford University), Kristen M. O'Dwyer(University of Rochester Medicine), Virginia Tan(Oregon Health & Science University), Timothy E. O’Connor(University of Northern Iowa), Ross McCauley(Roswell Park Comprehensive Cancer Center), Nikeshan Jeyakumar(Stanford Blood Center), Amy Zhang, Stephanie Tsai(Loyola University Medical Center), Ken Byrd(University of Kansas), Katherine Sutherland, Katharine Miller(Stanford University), Jozal Moore(University of Rochester Medicine), Ali Al-Darobi(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783